文献速递血栓与止血浆细胞疾病白血病

安全网医疗系统癌症患者动脉血栓栓塞的发生率与风险

Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system.
PubMed 文献 · J Thromb Haemost · 2025-02-03

该回顾性队列研究纳入2011至2021年在一家安全网医院系统新诊断浸润性癌症的17236例患者,采用累积发生率竞争风险法和多变量Fine-Gray模型分析动脉血栓栓塞(ATE)的发生率及风险因素。癌症诊断后1年ATE发生率为1.5%(95%CI 1.3%-1.6%),5年为2.8%(95%CI 2.5%-3%)。多变量调整后,仅癌症类型与已知心血管风险因素(高龄、吸烟、糖尿病、高血压、心肌梗死史、缺血性卒中史)仍与ATE显著相关。

要点

  • 癌症诊断后1年ATE发生率为1.5%,5年为2.8%。
  • 未调整分析中5年ATE发生率最高的为多发性骨髓瘤(8.6%)和急性白血病(7.8%)。
  • 多变量调整后,癌症类型和传统心血管风险因素均与ATE独立相关。

核心结论

  • 癌症类型和传统心血管风险因素均与癌症患者动脉血栓栓塞的发生独立相关。

研究设计与样本

  • 回顾性队列研究,纳入2011至2021年在一家安全网医院系统新诊断浸润性癌症的17236例患者(45.4%男性,中位年龄56岁)。
  • 采用验证过的住院账单诊断代码判定心肌梗死和缺血性卒中作为ATE结局。
  • 采用累积发生率竞争风险法考虑早期死亡,并使用多变量Fine-Gray模型估计亚分布风险比。

主要发现

  • 癌症诊断后1年ATE发生率为1.5%(95%CI 1.3%-1.6%),5年为2.8%(95%CI 2.5%-3%)。
  • 未调整分析中,5年ATE发生率在多发性骨髓瘤为8.6%、急性白血病为7.8%,接受免疫检查点抑制剂者为8.3% vs 未接受者为2.7%,东部肿瘤协作组体能状态4分者为5.4% vs 0分者为2.2%,IV期者为3.1% vs I期者为1.9%。
  • 多变量调整后,仅癌症类型与ATE显著相关,同时已知心血管风险因素(高龄、吸烟、糖尿病、高血压、心肌梗死史、缺血性卒中史)也与ATE显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The incidence of and risk factors for arterial thromboembolism (ATE) in patients with cancer, particularly in those with low socioeconomic status, remains understudied. OBJECTIVES: We aimed to report the association between cancer-related and cardiovascular (CV) risk factors and the development of ATE. METHODS: We performed a retrospective cohort study of patients with newly diagnosed invasive cancer from 2011 to 2021 at a safety-net hospital system. We ascertained ATE outcomes using validated inpatient billing diagnosis codes for myocardial infarction and ischemic stroke. We examined the incidence of ATE after cancer diagnosis using the cumulative incidence competing risk method to account for early mortality and estimated subdistribution hazard ratios for ATE using multivariable Fine-Gray models. RESULTS: Among 17 236 patients (45.4% male, median 56 years), the ATE incidence was 1.5% (95% CI, 1.3%-1.6%) at 1 year and 2.8% (95% CI, 2.5%-3%) at 5 years after cancer diagnosis. In unadjusted analysis, the 5-year ATE incidence was highest in hematologic malignancies, such as multiple myeloma (8.6%) and acute leukemia (7.8%), among patients receiving immune checkpoint inhibitors (8.3% vs 2.7%), those with poor Eastern Cooperative Oncology Group performance status (5.4% performance status 4 vs 2.2% performance status 0), and advanced stage (3.1% IV vs 1.9% I). After multivariable adjustment, only cancer type remained significantly associated with ATE along with known CV risk factors, including advanced age, smoking, diabetes, hypertension, history of myocardial infarction, and history of ischemic stroke. CONCLUSION: Both cancer type and traditional CV risk factors are independently associated with the development of ATE in patients with cancer.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Kim RB, Ryu JH, Guffey D, et al. Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system. J Thromb Haemost. 2025. PMID: 39909143. doi:10.1016/j.jtha.2025.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。